第1个回答 2010-07-05
杜绝机译，请楼主明鉴并费心审阅
Although extremely efficient in achieving complete medical
castration and well tolerated, with no other side effects
than the expected hypoandrogenicity GnRH agonists should not be administered alone. 虽然达到完全的医学阉割极为有效，而且得到很好的容忍，也没有除预料的雄激素缺乏之外的其他副作用，但肾上腺素受体激动药却不应该单独受到管制。In fact, shortly after discovery of the castration effects of GnRH agonists, we observed that
approximately 50% of androgens remain in the prostate after
castration, thus leading to the recognition of the role of adrenal dehydroepiandrosterone as an important source of the androgens synthesized locally in the prostate and in many
peripheral target tissues. 事实上，在发现肾上腺素受体激动药的（医学）阉割效应之后不久，我们就观察到大约50%的雄性激素在阉割后留存在前列腺中，从而导致了我们对肾上腺脱氢表雄酮作为一种在前列腺和很多周围的靶组织局部合成的雄性激素的认识。
We therefore developed combined androgen blockade (CAB), whereby the androgens of both testicular睾丸的 and adrenal origins are blocked simultaneously at start of treatment with the combination of a GnRH agonist to block the testis and a pure antiandrogen to block the action of the androgens produced locally. 因此我们开发了联合雄激素阻断（CAB），由此，在用肾上腺素受体激动药阻断睾丸结合单纯的抗雄性激素来阻断局部产生的雄性激素的作用来治疗的开始就同时阻断了睾丸的和肾上腺起源的雄性激素。
CAB, first used in advanced metastatic disease, has been the first treatment shown
to prolong life in prostate cancer. Most interestingly, in 2002, we made the observation that CAB alone given continuously for 6.5 yr or more leads to cure of the disease in at least 90% of cases, thus suggesting that androgen blockade combining a GnRH agonist and a pure antiandrogen could well be the most efficient treatment of localized prostate cancer, and thus offering the possibility of practically eliminating death from
prostate cancer.
首先用于晚期转移性疾病的CAB，它一直是证明能延长前列腺癌生命的首次治疗。最有意义的是在2002年，我们进行了观察，连续给予6.5年或更长时间的单纯的CAB导致了在至少90%的病例中疾病的治愈，因此告诉了我们，结合肾上腺素受体激动药和单纯抗雄性激素的雄性激素阻断可以很好地成为局部前列腺癌最有效的治疗方法，也因此提供了实际消除因前列腺癌而死亡的可能性
第2个回答 2010-07-06
Although extremely efficient in achieving complete medical castration and well tolerated, with no other side effects than the expected hypoandrogenicity, GnRH agonists should
not be administered alone. In fact, shortly after discovery of the castration effects of GnRH agonists, we observed that approximately 50% of androgens remain in the prostate after
castration, thus leading to the recognition of the role of adrenal dehydroepiandrosterone as an important source of the androgens synthesized locally in the prostate and in many
peripheral target tissues.
’促性腺激素释放激素’（GnRH）激动剂对于实现完整内科去势具有极佳的效果与良好的耐受性，除了可预见的雄激素缺乏，没有其他副作用。尽管如此，GnRH激动剂还是不适于单独给药。其实，在发现GnRH 激动剂的去势效果不久之后，我们观察到在去势后尚有约50%的雄性激素留在前列腺；这使我们认识到肾上腺去氢表雄酮在前列腺及许多外周组织局部合成雄性激素作为主要来源的角色。
We therefore developed combined androgen blockade (CAB), whereby the androgens of both testicular and adrenal origins are blocked simultaneously at start of treatment with the combination of a GnRH agonist to block the testis and a pure antiandrogen to block the action of the androgens produced locally.
我们因此研发了’联合阻断雄激素’治疗法（CAB），在开始治疗时就用双管齐下方式，同时以GnRH激动剂阻断睾丸源性雄激素，及通过全抗雄激素法阻止局部雄激素的产生。
CAB, first used in advanced metastatic disease, has been the first treatment shown to prolong life in prostate cancer. Most interestingly, in 2002, we made the observation that CAB alone given continuously for 6.5 yr or more leads to cure of the disease in at least 90% of cases, thus suggesting that androgen blockade combining a GnRH agonist and a pure antiandrogen could well be the most efficient treatment of localized prostate cancer, and thus offering the possibility of practically eliminating death from prostate cancer.
CAB最早用于治疗晚期的转移性疾病，一直被认为是延长前列腺癌患者生命的第一治疗法。最有意义的是我们在2002年观察到，持续6.5年或更长时间单独施与CAB治疗法，可以治愈至少90%的病例；由此显示，结合GnRH激动剂与全抗雄激素法来阻断雄激素，这可能是对局部前列腺癌最有效的治疗方法；也为消除因前列腺癌而死亡提供临床可能性。
【英语牛人团荣誉成员】
第3个回答 2010-07-22
Although extremely efficient in achieving complete medical
castration and well tolerated, with no other side effects
than the expected hypoandrogenicity GnRH agonists should not be administered alone.
虽然（促性腺激素释放激素激动剂）被用于彻底的医学上的男性生殖器切除极为有效，并且（病人）的耐受性良好。除了预料中雄激素缺乏之外并无其他副作用，但促性腺激素释放激素激动剂却不应该单独给药。
In fact, shortly after discovery of the castration effects of GnRH agonists, we observed that approximately 50% of androgens remain in the prostate after castration, thus leading to the recognition of the role of adrenal dehydroepiandrosterone as an important source of the androgens synthesized locally in the prostate and in many peripheral target tissues.
事实上，在发现肾上腺素受体激动药用于男性生殖器切除的效应不久之后，我们观察到在阉割手术后在前列腺中仍保留有大概50%的雄性激素，从而让我们对肾上腺脱氢表雄酮作为一种在前列腺，以及很多外围靶组织局部合成雄性激素的重要来源有了认识。
We therefore developed combined androgen blockade (CAB), whereby the androgens of both testicular睾丸的 and adrenal origins are blocked simultaneously at start of treatment with the combination of a GnRH agonist to block the testis and a pure antiandrogen to block the action of the androgens produced locally.
我们因此而开发了联合雄性激素阻断技术（简称CAB），因此，在我们开始使用联合疗法（即用促性腺激素释放激素激动剂阻断睾丸激素分泌，以及用单纯的抗雄性激素阻断局部雄性激素分泌）的时候，睾丸和肾上腺分泌的激素就几乎被同时阻断了。
CAB, first used in advanced metastatic disease, has been the first treatment shown to prolong life in prostate cancer. Most interestingly, in 2002, we made the observation that CAB alone given continuously for 6.5 yr or more leads to cure of the disease in at least 90% of cases, thus suggesting that androgen blockade combining a GnRH agonist and a pure antiandrogen could well be the most efficient treatment of localized prostate cancer, and thus offering the possibility of practically eliminating death from
prostate cancer.
CAB首先被用于晚期癌细胞转移疾病的治疗，它被证明是能够延长前列腺癌病人生命的第一疗法。最有趣的是，在2002年的是很，我们进行了观察，对病人进行为期连续六年半或更长时间的CAB单独给药疗法，有至少90%的病人因此而被治愈。
这表明了，结合了促性腺激素释放激素激动剂以及单纯抗雄性激素的联合雄激素疗法是可被用于局部前列腺癌的最有效的疗法，它因此而提供了在事实上消除前列腺癌病人死亡的可能性。
【译者按：太专业了，有些词汇拿捏不准，但总体应该没问题，如果觉得您能读懂，就是我莫大的欣慰了。】
第4个回答 2010-07-17
Although extremely efficient in achieving complete medical castration and well tolerated, with no other side effects than the expected hypoandrogenicity , GnRH agonists should not be administered alone.
尽管促性腺激素释放激素协同剂能高效的达成完整的医疗阉割技术，具有良好耐受性而且没有比预想中（瘦素hypoandrogenicity）的其他的副作用，但是它还是不应单独进行管理。
In fact, shortly after discovery of the castration effects of GnRH agonists, we observed that approximately 50% of androgens remain in the prostate after castration, thus leading to the recognition of the role of adrenal dehydroepiandrosterone as an important source of the androgens雄激素 synthesized合成的 locally in the prostate前列腺 and in many peripheral target tissues.
事实上，在发现促性腺激素释放激素协同剂不久之后，我们发现大约50％的雄激素在前列腺被阉割后仍然存在，从而导致了肾上腺脱氢表雄酮酯在前列腺和许多外围靶组织中的重要作用，而且它是合成的雄激素的重要来源。
We therefore developed combined androgen blockade (CAB), whereby the androgens of both testicular and adrenal origins are blocked simultaneously at start of treatment with the combination of a GnRH agonist to block the testis and a pure antiandrogen to block the action of the androgens produced locally.
因此，我们凭借是在治疗开始，不论是来自睾丸还是肾上腺分泌的雄激素都同时被封锁，而且我们可以凭借阻止睾丸的促性腺激素释放激素协同剂和阻止自身产生的雄激素行为的纯抗雄激素的结合， 来开发联合雄激素阻断治疗（CAB）技术。
CAB, first used in advanced metastatic disease, has been the first treatment shown to prolong life in prostate cancer.Most interestingly, in 2002, we made the observation that CAB alone given continuously for 6.5 yr or more leads to cure of the disease in at least 90% of cases, thus suggesting that androgen blockade combining a GnRH agonist and a pure antiandrogen could well be the most efficient treatment of localized prostate cancer, and thus offering the possibility of practically eliminating death from prostate cancer.
联合雄激素阻断治疗（ABC）技术在先进的转移性疾病中首次使用，它已被证明是第一种治疗前列腺癌的药物而且能延长生命。最有趣的是，在2002年，我们发现仅给予CAB 6年半或更多，导致至少治愈了90％的病例，从而表明阻止了促性腺激素释放激素协同剂和纯抗雄激素的结合的雄激素，很可能是局部前列腺癌最有效的治疗，从而提供了切实消除因前列腺癌死亡的可能性。
自己翻译，可以参考··
第5个回答 2010-07-05
由于没有其他任何副作用相反却产生预期的男性激素缺乏，即使在完成整个医疗阉割手术中有非常好的效果并且也有很好的耐药性，也不应该单独处置促性腺激素-释放荷尔蒙（GnRH）主动（缩）肌。事实上，发现GnRH主动（缩）肌阉割效果不久，我们观察到大约50%的男性激素早阉割以后还残留在前列腺中，从而导致作为在前列腺和边缘神经系统靶点组织里局部合成的男性激素重要资源的肾上腺脱氢表雄酮作用的识别。
因此我们研制了组合男性激素阻断（CAB），为阻塞睾丸和纯抗雄激素以阻塞局部产生的男性激素的作用，由此睾丸和肾上腺源点二个方面的男性激素在手术开始就与GnRH收缩筋的组合同时被阻断。 CAB第一次在复杂的新陈代谢疾病中使用，目前已经证明是在前列腺癌中的首选治疗。更有趣的是，2002年，我们进行了观察，单独进行连续6.5年或更长时间CAB导致至少在90%病例中得到治愈，因此我们建议结合GnRH收缩筋和纯抗雄激素的男性激素阻断，可能是最有效的局部前列腺癌的治疗，同时我们提供了事实上排除由前列腺癌引起死亡的可能性